

Invitrocue appoints independent non-executive director

23 October 2018 | News

Dr. Gary W. Pace brings more than 40 years of experience in the development and commercialization of advanced life sciences and related technologies, including biotechnology, pharmaceuticals and medical devices.



Singapore – Invitrocue Limited, a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Dr. Gary W. Pace as an Independent Non-Executive Director with immediate effect.

Dr. Gary W. Pace brings more than 40 years of experience in the development and commercialization of advanced life sciences and related technologies, including biotechnology, pharmaceuticals and medical devices. He is a serial entrepreneur and has held senior positions in small to large-scale life sciences ventures and companies in Australia, the USA and Europe. Dr. Pace is currently a director of ResMed, Pacira Pharmaceuticals and Simavita Ltd and Antisense Therapeutics Ltd as well as several private companies.

Dr. Pace has actively contributed to the development and growth of the global Life Sciences and Healthcare industry through honorary university appointments and industry and government committees. He was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was also awarded Director of the Year (corporate governance) by the San Diego Directors Forum.

Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology (MIT) where he was a Fulbright Fellow and General Foods Scholar. He has also held visiting academic positions at the Massachusetts Institute of Technology and the University of New South Wales and University of Queensland. He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering.

Commenting on the appointment, Dr. Steven Fang, Chief Executive Director, Invitrocue, said, “Dr. Pace brings not only impressive commercial experience from international healthcare companies but he is also a well-respected researcher who has written and co-written more than 30 research papers, reviews and patents. We look forward to his guidance and contributions as we continue with the international roll-out of our Onco-PDO Personalised Oncology testing services, and in broadening our menu of validated tumour types, changing the way cancers are being treated one patient at a time.”